

## News Release

### Biofrontera AG selects designated sponsor in Germany

Leverkusen, Germany, 22 January 2015 – Biofrontera announces today that it has selected Lang und Schwarz AG, Düsseldorf, as its sole designated sponsor in Germany. The company has terminated its designated sponsorship agreement with M.M. Warburg & CO effective 31 December 2014. Accordingly, the analyst research on Biofrontera previously performed by M.M. Warburg AG has been discontinued

For the London Stock Exchange's AIM market, Shore Capital continues to act as Nomad (Nominated Advisor) and Broker to Biofrontera.

#### Enquiries, please contact:

<b>Biofrontera AG</b>	+49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chairman of the Management Board	<a href="mailto:press@biofrontera.com">press@biofrontera.com</a>
Thomas Schaffer, Chief Financial Officer	<a href="http://www.biofrontera.com">www.biofrontera.com</a>
<b>IR Germany: Brainwell Asset Solutions</b>	+49 (0) 152 08931514
Jürgen Benker	
<b>Nomad and Broker: Shore Capital</b>	+44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs	
<b>IR UK: Seton Services</b>	+44(0) 20 7603 6797
Toni Vallen	
<b>Financial PR: Gable Communications</b>	+44(0) 20 7193 7463
John Bick	+44 (0)7872 061007

#### Background:

The **Biofrontera Group** (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is **Ameluz®**, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos® cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

## News Release

*This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.*